APRE

Aprea is a pre-revenue clinical-stage oncology company whose own 10-K states management has 'identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.' The numbers confirm it: $14.6M cash against $12.9M of annual operating cash burn leaves roughly one year of runway, and total assets fell 33.6% YoY to $15.9M. There is no product revenue and never has been (five straight years of losses: -$37.1M, -$113M, -$14.3M, -$13.0M, -$12.6M), so the entire equity value rests on two early clinical assets. ROE is -101% and accumulated deficit is -$334M.

Survival requires more capital, and the cost is dilution the shareholder is already paying for: shares outstanding jumped 108.5% YoY to 11.5M, which is why diluted EPS 'improved' to -$1.93 despite a similar-sized loss. The company also flags that it may be delisted if it fails minimum listing requirements — a live threat with the stock at $0.74, below the typical $1.00 minimum bid. A delisting would further impair its ability to raise the very equity it depends on. The balance sheet itself is clean (liabilities/equity just 0.26x), but that is cold comfort when the equity is being consumed by cash burn, not debt.